SEHK:2522Healthcare
Jiangxi Rimag Group SEHK 2522 Returns To Profit In FY 2025 H1 Yet Trails Bearish Narrative
Latest Earnings Set the Stage for Jiangxi Rimag Group (SEHK:2522)
Jiangxi Rimag Group (SEHK:2522) has just reported its FY 2025 first half results, with revenue of C¥467.0 million and basic EPS of C¥0.046, against a backdrop of trailing 12 month revenue of C¥813.9 million and a loss per share of C¥0.093. Over recent periods the company has seen revenue move from C¥413.7 million and EPS of C¥0.011 in 2024 H1 to C¥346.9 million and an EPS loss of C¥0.140 in 2024 H2, before landing at the latest...